Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.

Bendell, J; O'Reilly, E M; Middleton, M R; Chau, I; Hochster, H; Fielding, A; Burke, W; Burris, H

Bendell, J; O'Reilly, E M; Middleton, M R; Chau, I; Hochster, H; Fielding, A; Burke, W; Burris, H.

Affiliation

Bendell J; Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville. Electronic address: jbendell@tnonc.com.
O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, USA.
Middleton MR; Department of Oncology, University of Oxford, Oxford.
Chau I; Department of Medicine, Royal Marsden Hospital, Sutton, UK.
Hochster H; Yale Cancer Center, Yale School of Medicine, New Haven, USA.
Fielding A; Global Medicines Development, AstraZeneca.
Burke W; Clinical Pharmacology, AstraZeneca, Macclesfield, UK.
Burris H; Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville.

Ann Oncol ; 26(4): 804-811, 2015 Apr.

Article in En | MEDLINE | ID: mdl-25573533

Subject(s)
Key words

gemcitabine; olaparib; pancreatic cancer

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2015 Document type: Article Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google